NEW YORK, Dec. 24, 2014 (GLOBE NEWSWIRE) -- Rosen Law Firm reminds purchasers of Sarepta Therapeutics, Inc. stock (Nasdaq:SRPT) during the period from April 21, 2014 through October 27, 2014 of the important February 9, 2015 lead plaintiff deadline in the class action lawsuit.
To join the Sarepta class action, go to the website http://www.rosenlegal.com/cases-461.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The suit alleges that the Company (1) failed to provide sufficient data for its New Drug Application (NDA) submission for marketing approval of eteplirsen; and (2) as a result, the Company's NDA for eteplirsen would likely be filed in mid-2015, rather than the end of 2014. On October 27, 2014, following an announcement by the Company regarding additional data required for NDA approval, Sarepta's share price fell $7.65 per share or approximately 32% to close at $15.91/share, damaging investors.
If you wish to join the class action and recover your losses please go to http://www.rosenlegal.com/cases-461.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.